Cedazuridine clinical trials
Counted the way a researcher would: Cedazuridine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses cedazuridine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cedazuridine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 7 Jul 2020 · INQOVI · NDA 212576 (FDA, Drugs@FDA; in a combination)
- European Union
- 15 Sept 2023 · Inaqovi · EMEA/H/C/005823 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 8
Rutgers, The State University of New Jersey (2) · Taiho Oncology, Inc. (2) · Otsuka Australia Pharmaceutical Pty Ltd (1) · Astex Pharmaceuticals, Inc. (1) · PETHEMA Foundation (1) · National Cancer Institute (NCI) (1) · M.D. Anderson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Decitabine (11) · Venetoclax (3) · Azacitidine (1) · Hydroxychloroquine (1) · Ivosidenib (1) · Olutasidenib (1) · Avapritinib (1) · Defactinib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test cedazuridine, phase 3 first.
- Nov 2027A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)Phase 2/3 · Taiho Oncology, Inc.
- Mar 2027Avapritinib With Decitabine in Patients With SM-AHNPhase 1 · H. Lee Moffitt Cancer Center and Research Institute
- Jun 2027Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibPhase 1/2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses cedazuridine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsRecruitingPhase 2PETHEMA FoundationNCT07507760Written as Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
- Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaRecruitingPhase 2National Cancer Institute (NCI)NCT05960773Written as Decitabine/cedazuridine
- Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AMLNot yet recruitingPhase 2Rutgers, The State University of New JerseyNCT07867626Written as decitabine/cedazuridine
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)RecruitingPhase 2/3Taiho Oncology, Inc.NCT04256317Written as Cedazuridine
- Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06445959Written as Decitabine/cedazuridine
- Hydrochloroquinine & Decitabine With Venetoclax in AMLNot yet recruitingPhase 1Rutgers, The State University of New JerseyNCT07814339Written as Oral Decitabine/cedazuridine
- Avapritinib With Decitabine in Patients With SM-AHNRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06327685Written as Decitabine/Cedazuridine
- Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSRecruitingPhase 1Clinical Hub for Interventional Research (CHOIR)NCT05636514Written as Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
- A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)TerminatedPhase 1Taiho Oncology, Inc.NCT05403450Written as Decitabine + Cedazuridine
- Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell TransplantTerminatedPhase 2Sanjay MohanNCT05799079Written as Cedazuridine
- A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic LeukemiaActive, not recruitingPhase 3Otsuka Australia Pharmaceutical Pty LtdNCT05883956Written as Oral decitabine/cedazuridine
- Thorough QT Assessment of Cedazuridine in Healthy SubjectsCompletedPhase 1Astex Pharmaceuticals, Inc.NCT04953923Written as Cedazuridine
- A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic SyndromesWithdrawnPhase 2TakedaNCT04985656Written as Cedazuridine
Given beside what is tested · 3 — cedazuridine is usual care or a partner of the new treatment
- Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid TumorsActive, not recruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03875287Written as Cedazuridine
- Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPNActive, not recruitingPhase 1Jacqueline Garcia, MDNCT03613532Written as Decitabine/cedazuridine
- A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)TerminatedPhase 2Astex Pharmaceuticals, Inc.NCT05835011Written as Decitabine/Cedazuridine
Codes
What other systems call cedazuridine · ClinicalTrials.gg INT001153
- MeSH (NLM) C000633944cedazuridineOne source NLM
- UNII (FDA) 39IS23Q1EWCEDAZURIDINEConfirmed FDA, NLM
- RxNorm 2384449One source FDA
- NCI Thesaurus C164146CedazuridineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000633944 | cedazuridine | One source NLM |
| UNII (FDA) | 39IS23Q1EW | CEDAZURIDINE | Confirmed FDA, NLM |
| RxNorm | 2384449 | — | One source FDA |
| NCI Thesaurus | C164146 | Cedazuridine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.